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Previous studies showed that low serum bilirubin
concentrations are associated with increased risk of
cardiovascular disease. To explore this further, we evaluated
the relationships between serum bilirubin concentrations
and the degree of urinary albumin excretion and other
markers of subclinical atherosclerosis in 633 consecutive
patients with type 2 diabetes. Multiple regression analysis
showed that the serum bilirubin concentration was an
independent determinant of and had a significant inverse
correlation to the log urinary albumin excretion. Serum
bilirubin concentrations were significantly lower in patients
with than in those without cardiovascular disease.
A significant inverse correlation was found between the
serum bilirubin concentration and pulse wave velocity, while
a significant positive correlation was found to the ankle-
brachial index in a subgroup of 386 patients. Our study
shows that the serum bilirubin level is associated with
microalbuminuria and subclinical atherosclerosis in patients
with type 2 diabetes.
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Cardiovascular disease (CVD) is the leading cause of
mortality and morbidity in patients with type 2 diabetes.1,2
Previous studies have reported that low serum bilirubin
concentrations are associated with an increased risk of
CVD.3,4 Conversely, higher serum bilirubin concentrations
were associated with decreased risk of CVD in a prospective
study of serum bilirubin and CVD in the Framingham
Offspring Study.5 Furthermore, individuals with Gilbert
syndrome, who have mildly elevated serum bilirubin
concentration, were found to have a low rate of CVD.6
Recently Inoguchi et al.7 reported lower prevalence of
vascular complications (for example coronary artery disease,
cerebrovascular disease, retinopathy, or macroalbuminuria)
in patients with diabetes and Gilbert syndrome.
Oxidized low-density lipoprotein may be important in the
atherosclerotic process. Studies indicate that bilirubin, a
major intravascular product of heme catabolism, is an
effective antioxidant that effectively scavenges peroxyl
radicals and suppress the oxidation of lipids and lipoproteins
and thus acts against plaque formation and subsequent
atherosclerosis.8 Although previous studies have shown that
elevated serum bilirubin concentrations provide protection
against atherosclerotic disease, it is not clear whether higher
serum bilirubin concentrations work in favor of the
cardiovascular system in patients with type 2 diabetes.
Moreover, there has been no study investigating the effects
of serum bilirubin concentrations on diabetic nephropathy.
Elevated urinary albumin excretion has been reported to be a
marker of CVD as well as degree of diabetic nephropathy.9 In
this study, we evaluated the relationships between serum
bilirubin concentrations and degree of urinary albumin
excretion as well as markers of subclinical atherosclerosis
such as pulse wave velocity (PWV) or ankle-brachial index
(ABI) in patients with type 2 diabetes.
RESULTS
Characteristics of the 633 patients with type 2 diabetes
enrolled in this study are shown in Table 1. Relationships
between serum bilirubin concentration and other variables
are shown in Table 2. Duration of diabetes and serum
triglyceride concentration were inversely associated with
serum bilirubin concentration. Age at onset and diastolic
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blood pressure were positively associated with serum
bilirubin concentration. An inverse correlation was found
between serum bilirubin concentration and PWV
(r¼0.114, P¼ 0.0288), whereas a positive correlation was
found between serum bilirubin concentration and ABI
(r¼ 0.118, P¼ 0.0201). A positive correlation was found
between serum bilirubin concentration and estimated
glomerular filtration rate (r¼ 0.106, P¼ 0.0265). An inverse
correlation was found between serum bilirubin concentration
and logarithmic (log) (urinary albumin excretion)
(r¼0.202, Po0.0001; Figure 1). Multiple regression
analysis demonstrated that age, duration of diabetes,
hemoglobin A1C (HbA1c), systolic blood pressure, serum
triglyceride concentration, and serum bilirubin concentration
were independent determinants of log (urinary albumin
excretion) (Table 3). Comparisons of serum bilirubin
concentration in various groups are shown in Table 4. Serum
bilirubin concentrations were lower in female patients than in
male patients (P¼ 0.0032). Serum bilirubin concentrations
were lower in patients with proliferative diabetic retinopathy
than in patients with no diabetic retinopathy (P¼ 0.0017).
Serum bilirubin concentrations were lower in patients with
Table 2 | Correlation between serum bilirubin concentration
and other variables
r P
Age 0.010 0.8107
Age at onset 0.115 0.0063
Duration of diabetes 0.140 0.0008
BMI 0.035 0.3962
HbA1c 0.066 0.1015
Systolic blood pressure 0.012 0.7642
Diastolic blood pressure 0.120 0.0034
Total cholesterol 0.019 0.6403
Triglyceride 0.082 0.0435
HDL cholesterol 0.057 0.1548
Pulse wave velocity 0.114 0.0288
Ankle-brachial index 0.118 0.0201
Estimated glomerular filtration rate 0.106 0.0265
BMI, body mass index; HbA1c, hemoglobin A1C; HDL, high-density lipoprotein.
4
3.5
3
2.5
2
1.5
0.5
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2
1
0
Bilirubin (mg/100 ml)
lo
g 
(ur
in
ar
y 
al
bu
m
in
 e
xc
re
tio
n)
(m
g/g
 C
r)
r = –0.202
P < 0.0001
Figure 1 | Correlation between serum bilirubin concentration
and log (urinary albumin excretion) in patients with type 2
diabetes.
Table 3 | Simple correlation and multiple regression analysis
on log UAE
r P Partial r b P
Age 0.146 0.0002 0.130 0.133 0.0048
Sex — — 0.017 0.018 0.7189
Duration of diabetes 0.197 o0.0001 0.149 0.149 0.0013
BMI 0.135 0.0011 0.024 0.024 0.6049
HbA1c 0.217 o0.0001 0.123 0.116 0.0080
Systolic blood pressure 0.319 o0.0001 0.253 0.243 o0.0001
Total cholesterol 0.080 0.0497 0.015 0.014 0.7533
Triglyceride 0.203 o0.0001 0.188 0.189 o0.0001
Smoking status — — 0.015 0.016 0.7498
Bilirubin 0.202 o0.0001 0.212 0.195 o0.0001
BMI, body mass index; HbA1c, hemoglobin A1C; UAE, urinary albumin excretion.
b indicates standardized regression coefficients.
Table 1 | Clinical characteristics of patients with diabetes
Mean±s.d.
n 633
Sex (male/female) 331/302
Age (years) 64.4±11.5
Age at onset (years) 50.5±12.7
Duration of diabetes (years) 13.8±11.1
BMI (kg/m2) 23.1±3.6
HbA1c (%) 7.3±1.2
Systolic blood pressure (mm Hg) 133±16
Diastolic blood pressure (mm Hg) 75±10
Total cholesterol (mmol/l) 5.17±0.88
Triglyceride (mmol/l) 1.48±0.99
HDL cholesterol (mmol/l) 1.42±0.41
Aspartate aminotransferase (IU/l) 23±11
Alanine aminotransferase (IU/l) 22±14
Alkaline phosphatase (IU/l) 243±89
g-Glutamyltransferase (IU/l) 30±22
Creatinine (mg/100 ml) 0.79±0.27
Smoking (none/past/current) 315/163/155
Retinopathy (NDR/SDR/PDR) 424/88/121
Nephropathy (normo-/micro-/macroalbuminuria) 371/191/71
Cardiovascular disease (/+) 545/88
Diabetic treatment (diet/oral hypoglycemic agents/insulin) 58/401/174
Hypertensive treatment (/+) 273/370
Hyperlipidemic treatment (/+) 437/196
Pulse wave velocity (cm/s) 1815±386
Ankle-brachial index 1.08±0.15
Serum bilirubin (mg/100 ml) 0.71±0.20
BMI, body mass index; HbA1c, hemoglobin A1C; HDL, high-density lipoprotein; NDR,
no diabetic retinopathy; SDR, simple diabetic retinopathy; PDR, proliferative diabetic
retinopathy.
Data are mean±s.d. or number of patients.
Table 4 | Comparisons of serum bilirubin concentration in
various groups
Group Bilirubin (mean±s.d.)
Sex (male/female) 0.73±0.20/0.68±0.19
Retinopathy (NDR/SDR/PDR) 0.73±0.20/0.69±0.19/
0.66±0.20
Nephropathy (normo-/micro-/
macroalbuminuria)
0.73±0.19/0.69±0.21/
0.61±0.18
Cardiovascular disease (/+) 0.71±0.20/0.65±0.19
Insulin treatment (/+) 0.71±0.20/0.69±0.20
Smoking (none/past/current) 0.71±0.20/0.73±0.19/
0.68±0.19
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macroalbuminuria than in patients with normoalbuminuria
(Po0.0001) or microalbuminuria (P¼ 0.0012), and serum
bilirubin concentrations were lower in patients with micro-
albuminuria than in patients with normoalbuminuria
(P¼ 0.0418). Serum bilirubin concentrations were lower in
patients with CVD than without (P¼ 0.0053). Serum
bilirubin concentrations did not differ between patients
treated with and without insulin (P¼ 0.3863). Serum
bilirubin concentrations were lower in patients with current
smokers than in patients with past smokers (P¼ 0.0294).
DISCUSSION
Serum bilirubin concentration correlated negatively with
degree of urinary albumin excretion and correlated positively
with estimated glomerular filtration rate, which suggests that
bilirubin has a potential role for protection of diabetic
nephropathy. Multiple regression analysis also identified
serum bilirubin concentration as an independent determi-
nant of log (urinary albumin excretion).
Ollinger et al.10 found less balloon injury-induced
neointima formation in hyperbilirubinemic rats treated with
biliverdin, the precursor of bilirubin, than in controls, and
demonstrated that bilirubin inhibited serum-driven smooth
muscle cell-cycle progression at the G1 phase in vitro.
Bilirubin serves as a physiological antioxidant in ischemia-
reperfusion,11 and serves a protective function against injury-
mediated proliferation of intimal cells in animal models.12
On the basis of in vitro as well as animal studies, bilirubin is
generally recognized as an important antioxidant substance.
Kumar et al.13 demonstrated that serum bilirubin concentra-
tion correlated inversely with a marker of oxidative stress and
correlated positively with antioxidative enzyme activities such
as superoxide dismutase, catalase, and glutathione peroxidase
in jaundiced newborns. This is also supported by clinical
studies focused on the protective effect of serum bilirubin
concentrations on atherosclerosis.3–5 Our study demonstrated
that serum bilirubin concentrations were lower in patients
with CVD than without. Furthermore, serum bilirubin
concentrations correlated negatively with PWV and corre-
lated positively with ABI, which are early preclinical markers
of atherosclerosis, in patients with type 2 diabetes.
To explain plausible mechanisms of bilirubin action in
preventing atherosclerosis, several mechanisms have been
suggested. The most popular one is bilirubin-mediated
inhibition of lipid oxidation.8 Lipoproteins, particularly
low-density lipoprotein cholesterol, are highly susceptible
to oxidation, and it is known that the atherogenic process
involves uptake of oxidized low-density lipoprotein by
intimal macrophages leading to the accumulation of lipid-
rich foam cells. Given the antioxidant capacity of bilirubin, it
is plausible that bilirubin protects lipids and lipoproteins
against oxidation and thereby offers protection against
atherosclerosis. Bilirubin is a more effective protector of
human ventricular myocytes than several known antiox-
idants, such as vitamin C and vitamin E analogues.14 Free
bilirubin, albumin-bound bilirubin, conjugated bilirubin,
and unconjugated bilirubin were all noted to be effective
scavengers of peroxyl radicals and to be able to protect
human low-density lipoprotein against peroxidation.14,15
Besides being an antioxidant, bilirubin also has anticomple-
ment properties that protect against inflammation.16
Furthermore, bilirubin has been suggested to have cytopro-
tective properties through its influence on protein kinase C.
In vitro, protein kinase C increases the scavenger receptor
expression in smooth muscle cells and therefore contributes
to the formation of smooth muscle foam cells.17 Mietus-
Synder et al.17 demonstrated that hyperbilirubinemia can
improve endothelium-independent vasodilator functions of
the coronary vasculature. The mechanisms described above
are some of the important mechanisms of the development
and progression of diabetic nephropathy18–21 or retinopa-
thy,21,22 which may partially explain the association between
serum bilirubin concentration and degree of diabetic
nephropathy or retinopathy.
Surprisingly, the strength of serum bilirubin concentration
as an independent determinant of log (urinary albumin
excretion) was similar to those of known factors such as
systolic blood pressure, HbA1c, and duration of diabetes in
multiple regression analysis. Serum bilirubin concentration
was an independent determinant of log (urinary albumin
excretion) even after adjustment for treatment of hyperten-
sion and hyperlipidemia (Po0.0001). The clinical relevance
relates to potential preventive and therapeutic approaches.
Smoking was reported to be highly correlated with low serum
bilirubin concentration,4 which was also found in the present
study. Feasible strategies for boosting serum bilirubin
concentration may include administration of drugs which
decrease the efficacy of hepatic bilirubin conjugation such as
uricosuric drug probenecid,23 and administration of heme
oxygenase-1 inducers such as lipoic acid and various
bioavailable flavonoids.23 The diagnostic relevance concerns
the diagnostic utility of serum bilirubin concentrations, as a
provisional new risk factor of diabetic nephropathy as well as
atherosclerosis, which can be measured easily in the clinical
laboratory and applied in medical practice.
Limitations of our study include a cross-sectional design.
In addition, results in this study may not be applicable to
general population or to patients with type 2 diabetes in a
primary care clinic because patients in an outpatient clinic in
a university hospital are selected patients. Furthermore, we
have measured ABI oscillometrically, although Beckman
et al.24 demonstrated that oscillometric determination of
the ABI was a reliable and easier method, which correlated
well with Doppler ultrasound measurement of ABI. However,
to our knowledge, this is the first study to investigate the
relationship between serum bilirubin concentration and
urinary albumin excretion as well as subclinical athero-
sclerosis in patients with type 2 diabetes. Although we are
unable to determine whether hypobilirubinemia has a
causative effect, these findings suggest that hypobilirubinemia
combined with diabetes might be associated with advanced
diabetic nephropathy and atherosclerosis. Large prospective
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trials are needed to better assess the effects of bilirubin on
diabetic nephropathy and atherosclerosis in patients with
type 2 diabetes.
MATERIALS AND METHODS
Patients
Serum bilirubin concentrations were measured in 633 consecutive
patients with type 2 diabetes recruited from the outpatient clinic at
the Kyoto Prefectural University of Medicine. We then evaluated
relationships of serum bilirubin concentrations to degree of urinary
albumin excretion as well as to major cardiovascular risk factors,
including age, blood pressure, serum lipid concentration, and
glycemic control (HbA1c), body mass index (BMI), current
treatment for diabetes, smoking status, and presence of CVD. The
relationships between serum bilirubin concentrations and PWV or
ABI (n¼ 386) were investigated additionally in a subgroup of
patients.
Clinical and biochemical assessment
Type 2 diabetes was diagnosed according to the Report of the Expert
Committee on the Diagnosis and Classification of Diabetes
Mellitus.25 Retinopathy was assessed by ophthalmoscope, and was
graded as no diabetic retinopathy; simple diabetic retinopathy; or
proliferative diabetic retinopathy. Nephropathy was graded as
follows: normoalbuminuria, urinary albumin excretion less than
30 mg per gram of creatinine (mg/g Cr); microalbuminuria,
30–300 mg/g Cr; or macroalbuminuria, more than 300 mg/g Cr.
GFR was estimated from the Modification of Diet in Renal Disease
equation for Japanese patients.26 Sitting blood pressure was
measured after a 5-min rest. CVD was defined as a previous
myocardial or cerebral infarction based on the clinical history or
physical examination. Subjects were classified as nonsmokers, past
smokers, or current smokers according to a self-administered
questionnaire.
Patients with malignant disease, liver cirrhosis, or hematologic
disease were excluded from this study. Patients with advanced renal
dysfunction (serum creatinine more than 2.0 mg/100 ml) were also
excluded. Furthermore, patients, whose serum bilirubin concentra-
tions 41.2 mg/100 ml, were excluded because of the high possibility
of Gilbert syndrome. Approval for the study was obtained from the
local Research Ethics Committee, and informed consent was
obtained from all participants.
Blood samples were taken in the morning. Total serum bilirubin
concentrations (normal ranges: 0.2–1.0 mg/100 ml) were measured
by an enzymatic method with bilirubin oxidase on an automatic
analyzer (Hitachi 7600). Serum total cholesterol, high-density
lipoprotein cholesterol, and triglyceride concentrations were
assessed using standard enzymatic methods. HbA1c was assayed
using high-performance liquid chromatography. Urinary albumin
and creatinine concentration were determined in an early morning
spot urine. Urinary albumin excretion was measured with an
immunoturbidimetric assay. A mean value for urinary albumin
excretion was determined from three urine collections.
Measurement of pulse wave velocity and ankle-brachial
index
Brachial-ankle PWV and ABI were measured using a Colin
Waveform Analyzer (form PWV/ABI; Colin Medical Technology,
Komaki, Japan), which simultaneously measures pulse volumes in
the brachial and posterior tibial arteries using an oscillometric
method together with bilateral arm and ankle blood pressure. Both
PWV and ABI were measured after allowing the patient to rest in the
supine position for at least 5 min. For measuring brachial-ankle
PWV, pulse volume waveforms of the brachial and tibial arteries
were recorded. Details of the method have been described
elsewhere.27 After bilateral determination of brachial-ankle PWV,
the higher value was taken as representative for each subject. ABI
was calculated bilaterally as the ratio of systolic pressure in the ankle
to systolic pressure in the arm, with the lower value considered
representative for each subject.
Statistical analysis
Means and frequencies of potential confounding variables were
calculated. Unpaired Student’s t-tests or analyses of variance were
conducted to assess statistical significance of differences between
groups, using Stat View software (version 5.0; SAS Institute, Cary,
NC). Because urinary albumin excretion showed skewed distribu-
tions, log transformation was carried out before performing
correlation and regression analysis. The relationships between serum
bilirubin concentrations and log (urinary albumin excretion), PWV,
or ABI as well as the relationships between serum bilirubin
concentrations and age, glycemic control or other variables were
examined by Pearson’s correlation analyses. To examine the effects of
various factors on log (urinary albumin excretion), the following
factors were considered simultaneously as independent variables for
multiple regression analysis: serum bilirubin concentrations, age,
sex, duration of diabetes, BMI, HbA1c, systolic blood pressure,
serum total cholesterol, and triglyceride concentration and smoking
status. All continuous variables are presented as the mean±s.d. A P-
value o0.05 was considered statistically significant.
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